Benjamin F. Edwards & Company Inc. Grows Stock Holdings in Kenvue Inc. (NYSE:KVUE)

Benjamin F. Edwards & Company Inc. lifted its position in Kenvue Inc. (NYSE:KVUE) by 4.7% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 43,744 shares of the company’s stock after purchasing an additional 1,971 shares during the quarter. Benjamin F. Edwards & Company Inc.’s holdings in Kenvue were worth $795,000 at the end of the most recent quarter.

Other institutional investors have also recently modified their holdings of the company. Manchester Capital Management LLC raised its position in Kenvue by 80.8% in the 1st quarter. Manchester Capital Management LLC now owns 1,186 shares of the company’s stock worth $25,000 after purchasing an additional 530 shares during the period. Poehling Capital Management INC. lifted its stake in shares of Kenvue by 0.5% in the 2nd quarter. Poehling Capital Management INC. now owns 104,934 shares of the company’s stock valued at $1,908,000 after acquiring an additional 547 shares during the last quarter. Tradition Wealth Management LLC grew its position in Kenvue by 2.8% during the 4th quarter. Tradition Wealth Management LLC now owns 21,278 shares of the company’s stock worth $458,000 after acquiring an additional 575 shares during the last quarter. MV Capital Management Inc. increased its stake in Kenvue by 71.2% in the 1st quarter. MV Capital Management Inc. now owns 1,544 shares of the company’s stock worth $33,000 after purchasing an additional 642 shares during the period. Finally, Cove Private Wealth LLC lifted its position in Kenvue by 1.6% in the second quarter. Cove Private Wealth LLC now owns 44,539 shares of the company’s stock valued at $810,000 after purchasing an additional 700 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors.

Kenvue Trading Up 0.4 %

NYSE KVUE opened at $23.11 on Wednesday. The firm has a market capitalization of $44.25 billion, a PE ratio of 29.63, a P/E/G ratio of 2.92 and a beta of 1.40. The stock’s 50 day moving average is $21.12 and its 200 day moving average is $20.01. Kenvue Inc. has a twelve month low of $17.67 and a twelve month high of $23.55. The company has a quick ratio of 0.68, a current ratio of 0.99 and a debt-to-equity ratio of 0.69.

Kenvue (NYSE:KVUE) last announced its earnings results on Tuesday, August 6th. The company reported $0.32 EPS for the quarter, beating analysts’ consensus estimates of $0.28 by $0.04. The firm had revenue of $4 billion for the quarter, compared to analysts’ expectations of $3.93 billion. Kenvue had a net margin of 7.23% and a return on equity of 21.80%. The company’s quarterly revenue was down .3% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.32 EPS. Research analysts forecast that Kenvue Inc. will post 1.08 earnings per share for the current fiscal year.

Kenvue Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, August 28th. Shareholders of record on Wednesday, August 14th were paid a dividend of $0.205 per share. This is an increase from Kenvue’s previous quarterly dividend of $0.20. The ex-dividend date was Wednesday, August 14th. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.55%. Kenvue’s dividend payout ratio (DPR) is currently 105.13%.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the stock. Jefferies Financial Group assumed coverage on shares of Kenvue in a report on Tuesday. They issued a “buy” rating and a $27.00 target price on the stock. Deutsche Bank Aktiengesellschaft raised their price target on shares of Kenvue from $23.00 to $24.00 and gave the stock a “buy” rating in a report on Wednesday, August 7th. JPMorgan Chase & Co. increased their target price on shares of Kenvue from $22.00 to $24.00 and gave the stock an “overweight” rating in a report on Wednesday, August 7th. UBS Group boosted their price target on Kenvue from $20.00 to $22.00 and gave the company a “neutral” rating in a report on Wednesday, August 7th. Finally, Royal Bank of Canada cut Kenvue from an “outperform” rating to a “sector perform” rating and set a $24.00 price objective for the company. in a report on Tuesday. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and three have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $22.10.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.